Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
Olaf Neumann, Timothy C. Burn, Michael Allgäuer, et al.
British Journal of Cancer (2022) Vol. 127, Iss. 8, pp. 1540-1549
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M.F. Mosele, C. Benedikt Westphalen, A Stenzinger, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 588-606
Open Access | Times Cited: 80
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
J.E. Berchuck, Francesco Facchinetti, Daniel DiToro, et al.
Annals of Oncology (2022) Vol. 33, Iss. 12, pp. 1269-1283
Open Access | Times Cited: 79
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 56
High‐throughput molecular assays for inclusion in personalised oncology trials – State‐of‐the‐art and beyond
Anders Edsjö, Hege G. Russnes, Janne Lehtiö, et al.
Journal of Internal Medicine (2024) Vol. 295, Iss. 6, pp. 785-803
Open Access | Times Cited: 5
Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing
Albrecht Stenzinger, Arndt Vogel, Ulrich Lehmann, et al.
Cancer Treatment Reviews (2023) Vol. 122, pp. 102649-102649
Open Access | Times Cited: 14
Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts’ position paper
Matteo Fassan, Valentina Angerilli, Nicola Normanno, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 194, pp. 104224-104224
Open Access | Times Cited: 5
Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma
Younghoon Kim, Jaewon Song, Namkyoung Kim, et al.
RSC Medicinal Chemistry (2025)
Closed Access
CACA Technical guidelines for holistic integrative management of cancer —— genetic testing
Bing Wei, Jinliang Xing, Xiaoyan Zhou, et al.
Holistic Integrative Oncology (2025) Vol. 4, Iss. 1
Open Access
FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice
Valentina Angerilli, Lorenzo Fornaro, Francesco Pepe, et al.
Pathologica (2023) Vol. 115, Iss. 2, pp. 71-82
Open Access | Times Cited: 7
Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma: Current Progress, Mechanisms of Action, and Challenges
Dan Li, Lalitya Andaloori, Matthew Crowe, et al.
American Journal Of Pathology (2024)
Closed Access | Times Cited: 2
Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives
Alberto Pïcca, Giulio Sansone, Orazio Santo Santonocito, et al.
Cancers (2023) Vol. 15, Iss. 23, pp. 5555-5555
Open Access | Times Cited: 6
Pemigatinib: A Review in Advanced Cholangiocarcinoma
James E. Frampton
Targeted Oncology (2024) Vol. 19, Iss. 1, pp. 107-114
Closed Access | Times Cited: 1
Updates in Diagnosis and Endoscopic Management of Cholangiocarcinoma
Roxana-Luiza Caragut, Mădălina Ilie, Teodor Cabel, et al.
Diagnostics (2024) Vol. 14, Iss. 5, pp. 490-490
Open Access | Times Cited: 1
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations
Eranga R. Balasooriya, Qibiao Wu, Haley Ellis, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2181-2192
Closed Access | Times Cited: 1
Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma
Philipp Heumann, Andreas Albert, Karsten Gülow, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1690-1690
Open Access | Times Cited: 1
The Current Role of Radiation in the Management of Cholangiocarcinoma—A Narrative Review
Saurav Verma, Natalie Grindrod, Daniel Breadner, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1776-1776
Open Access | Times Cited: 1
Practical considerations for pathological diagnosis and molecular profiling of cholangiocarcinoma: an expert review for best practices
Matthew Evans, Timothy J. Kendall
Expert Review of Molecular Diagnostics (2024) Vol. 24, Iss. 5, pp. 393-408
Closed Access | Times Cited: 1
Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker
Patrick Sven Plum, Timo Hess, Denis Bertrand, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 6
Open Access | Times Cited: 1
Real-world use of pemigatinib for the treatment of cholangiocarcinoma in the US
Kim Saverno, Kristin M. Zimmerman Savill, Cherrishe Brown‐Bickerstaff, et al.
The Oncologist (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 1
Cholangiocarcinoma Targeted Therapies: Mechanisms of Action and Resistance
Haley Ellis, Chiara Braconi, Juan W. Valle, et al.
American Journal Of Pathology (2024)
Closed Access | Times Cited: 1
First proficiency testing for NGS‐based and combined NGS‐ and FISH‐based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma
Olaf Neumann, Ulrich Lehmann, Stephan Bartels, et al.
The Journal of Pathology Clinical Research (2023) Vol. 9, Iss. 2, pp. 100-107
Open Access | Times Cited: 4
Computational identification and exploration of novel FGFR tyrosine kinase inhibitors for the treatment of cholangiocarcinoma
Amanpreet Kaur, Debasish Mandal
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 23, pp. 13153-13164
Open Access | Times Cited: 3
Precision oncology for biliary tract tumors: it’s written in blood!
Mohamed A. Gouda, Vivek Subbiah
Annals of Oncology (2022) Vol. 33, Iss. 12, pp. 1209-1211
Closed Access | Times Cited: 5
Novel cell subtypes of SPP1 + S100P+, MS4A1-SPP1 + S100P+ were key subpopulations in intrahepatic cholangiocarcinoma
Zixue Xuan, Linqing Liu, Guobing Zhang, et al.
Biochimica et Biophysica Acta (BBA) - General Subjects (2023) Vol. 1867, Iss. 9, pp. 130420-130420
Closed Access | Times Cited: 2
Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications
Huriye Seker‐Cin, Timothy Kwang Yong Tay, Daniel Kazdal, et al.
Lung Cancer (2023) Vol. 184, pp. 107317-107317
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top